Our Firm is looking forward to the federal Lipitor litigation’s upcoming status conference, as we continue to hear from individuals who allegedly developed diabetes after taking Lipitor.
New York, NY (PRWEB) January 01, 2015
A federal litigation that includes hundreds of Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) is looking ahead to a status conference in January that will take place in the U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports.
According to a Calendar posted on the Court’s website, the meeting is scheduled for January 22nd, 2015 at 10:00 a.m., at which time parties will discuss issues related to claims alleging the cholesterol-lowering medication’s potential to cause Type 2 diabetes. Plaintiffs involved in Lipitor lawsuits filed in the jursidiction accuse the drug’s manufacturer, Pfizer Inc., of failing to properly warn about its possible association with the disease. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is looking forward to the federal Lipitor litigation’s upcoming status conference, as we continue to hear from individuals who allegedly developed diabetes after taking Lipitor,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective devices and drugs including Lipitor. The Firm is actively investigating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes after taking the medication.
According to court documents, hundreds of Lipitor lawsuits are moving forward in the federal multidistrict litigation underway in the U.S. District Court, District of South Carolina. As of December 15th, a total of 1,478 claims alleging Lipitor diabetes complications had been filed in the proceeding by plaintiffs who accuse Pfizer Inc. of failing to adequately warn about side effects associated with its product. The filing of these claims follows a federal mandate from the U.S. Food and Drug Administration (FDA) that in February 2012 required statin manufacturers to adjust the labeling on their products to reflect new information about a possible link to Type 2 diabetes. The FDA notice followed the results of a study published in JAMA: Internal Medicine that showed an increased risk of the disease in post-menopausal women on statins.*
Individuals who were diagnosed with Type 2 diabetes after taking Lipitor may be eligible to seek compensation for lost wages, out-of-pocket medical expenses and other injury-related damages that allegedly resulted from its use. Learn more about filing a Lipitor lawsuit when you visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 23, 2012.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com